UCB And Biogen Idec Discontinue Phase II Clinical Trial
Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients

post from ** Stu's Views & M.S. News ** on 03 July 2009 07:31:00 AM. © ** Stu's Views & M.S. News **

July 2, 2009
UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.

CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis.

Read More
============================================

Read The Full Article:
http://wwwmsviewsandrelatednews.blogspot.com/2009/07/ucb-and-biogen-idec-disconti
nue-phase.html